ArticleMolecular neurobiology2025
Characterization of Dystrophin Dp71 Expression and Interaction Partners in Embryonic Brain Development: Implications for Duchenne/Becker Muscular Dystrophy.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Multi-System Roles of Dp71 Dystrophin Isoforms in Duchenne Muscular Dystrophy.Muscles (Basel, Switzerland) · 2026Review
- RNA Therapeutics for Duchenne Muscular Dystrophy: Exon Skipping, RNA Editing, and Translational Insights from Genome-Edited Microminipig Models.International journal of molecular sciences · 2026Review
- Mutation of leucine 170 alters the subcellular distribution, neurite outgrowth and three-dimensional structure of dystrophins Dp71 and Dp40.Molecular biology reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Duchenne/Becker muscular dystrophy (DMD/BMD) manifests progressive muscular dystrophy and non-progressive central nervous disorder. The neural disorder is possibly caused by abnormalities in the developmental period; however, basic research to understand the mechanisms remains underdeveloped. The responsible gene, Dmd (dystrophin), generates multiple products derived from several gene promoters. Here, we aim to characterize the expression of the shortest product, Dp71, during embryonic brain development and to identify its interaction proteins by using Dp71-specific tag-insertion mice. We showed that Dp71 and Dp140 were major dystrophin products significantly detectable in the mouse embryonic brains and Dp71 was the only dystrophin product derived from intron-62 gene promoter in the physiological mouse brains. Although both Dp71f (exon 78-exclusive form) and Dp71d (exon 78-inclusive form) existed in the embryonic brains, Dp71f and Dp71d were dominant forms in the prenatal and postnatal periods, respectively. We histologically found that Dp71 was prominently expressed in the neuroepithelium of the dorsal and medial telencephalon, which gives rise to the primordial cerebral cortex and hippocampus. Deeper analysis using in vitro primary culture verified Dp71 expressions in Nestin-positive neural stem/progenitor, Fabp7-positive radial glia, and Gfap-positive astrocytic cell populations. Interestingly, Dp71 was downregulated upon neuronal differentiation from stem/progenitor cells into TuJ1-positive immature neurons; however, Dp71 became detectable at Gephyrin-positive inhibitory postsynapses within mature neurons. Importantly, interactome analysis revealed dystroglycan, dystrobrevins, and syntrophins as dominant Dp71-partners in the embryonic neural stem/progenitor cells. Thus, the presence of Dp71-dystroglycan macromolecular complex was clearly established at an early stage of embryonic brain development, which sheds light on relations between fetal abnormalities and intellectual disabilities in DMD/BMD.
Indexed as
Identifiers
39760982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.